To date, several human monoclonal antibodies pharmacologically blocking these interactions have been implemented in cancer therapy, such as the anti-PD-1 antibody pembrolizumab that has been approved in combination with chemotherapy for non-squamous NSCLC, irrespective of PD-L1 expression [27, 28]. This evidence concerns the gene PDCD1 and cancer.